Lucida Medical’s mission is to use artificial intelligence (AI) to optimise the prostate cancer pathway. Its flagship product, Pi™ (Prostate Intelligence), is a CE-marked medical device that supports the detection of prostate cancer from multi-parametric and bi-parametric MRI scans. Pi™ automates lesion detection, segmentation and provides risk scoring per patient and lesion. It can improve diagnostic accuracy, reduce missed cancers and unnecessary biopsies, and streamline clinical decisions across the pathway.
Lucida Medical is a spin off from Cambridge University, and is based in Cambridge, England. It was founded in 2018 by Dr Antony Rix, who has 25 years’ experience in AI and Machine Learning, and Professor Evis Sala, a globally recognised Radiologist in prostate and gynaecological imaging. They are supported by a team of AI engineers and scientists, as well as experts in clinical research, regulatory compliance, and experienced prostate Radiologists.
